<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To elicit clinical features of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> associated with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APSN) in patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: The analysis of clinical characteristics and course of APSN has covered 24 patients with PAPS (16 females and 8 males, mean age 34.3 years) </plain></SENT>
<SENT sid="2" pm="."><plain>Renal damage was represented by arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> (AH), urinary syndrome, functional decline </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients were tested for anticardiolipin antibodies and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Renal biopsy was made in 7 patients </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: PAPS patients developed renal affection in the <z:hpo ids='HP_0003674'>onset</z:hpo> of APS or within the first 5 years of its course </plain></SENT>
<SENT sid="6" pm="."><plain>In the majority of patients APSN combined with abnormalities of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>, heart and skin </plain></SENT>
<SENT sid="7" pm="."><plain>Arterial/arteriolar thromboses prevailed </plain></SENT>
<SENT sid="8" pm="."><plain>APSN manifested with: AH (n = 23, severe AH in 11), abnormal renal filtration (n = 17, <z:chebi fb="0" ids="16737">creatinine</z:chebi> rise in 8), urinary syndrome with <z:hpo ids='HP_0000093'>proteinuria</z:hpo> (n = 23, in 14 with <z:hpo ids='HP_0000790'>hematuria</z:hpo>) </plain></SENT>
<SENT sid="9" pm="."><plain>The following clinical variants of APSN were proposed: urinary syndrome with AH (n = 16; 67%), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0268732" disease_type="Disease or Syndrome" abbrv="">nephritic syndrome</z:e> (n = 7; 29%), <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> (n = 1) </plain></SENT>
<SENT sid="10" pm="."><plain>Morphological studies of biopsies from APSN patients have revealed sclerotic changes, <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e>, nonspecific alterations in the glomeruli </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: APSN is a variant of microvascular renal affection caused by thrombotic processes in intra-organ microcirculation </plain></SENT>
<SENT sid="12" pm="."><plain>It is an early clinical marker of APS </plain></SENT>
<SENT sid="13" pm="."><plain>Clinically, APSN manifests with vascular renal affection, the earliest symptom being inhibition of glomerular filtration </plain></SENT>
<SENT sid="14" pm="."><plain>Clinical combinations of the symptoms allow to distinguish variant of APSN suggesting the existence of <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> APSN </plain></SENT>
<SENT sid="15" pm="."><plain>Combination of APSN with affection of the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>, heart and skin points to a special PAPS subtype characterized by generalized ischemic damage to the organs as a result of intraorganic arterial and/or arteriolar thromboses </plain></SENT>
</text></document>